Recent Comments

Comment RSS

Abilify News and Research RSS Feed - Abilify News and Research

Aripiprazole (marketed as Abilify, Abilify Discmelt) is an atypical antipsychotic medication approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia.

FDA approves sNDA for pediatric autism drug ABILIFY

20. November 2009 23:40
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods. [More]

Posted in: Child Health News | Pharmaceutical News

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Permalink | Comments (0)

Bipolar disorder drug market to decline approximately $5 billion in 2018

6. November 2009 01:46
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that widespread generic erosion of branded atypical antipsychotics will cause the bipolar disorder drug market to decline from $6.3 billion in 2008 to approximately $5 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. [More]

Posted in: Pharmaceutical News

Tags: , , , , , , , ,

Permalink | Comments (0)

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

22. October 2009 08:08
Bristol-Myers Squibb Company today reported strong sales and earnings growth for the third quarter 2009. [More]

Posted in: Business / Finance

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Permalink | Comments (0)

The latest medication to treat schizophrenia "ABILIFY" launched in Canada

6. October 2009 07:49
A new treatment option for Canadians with schizophrenia, ABILIFY(TM) (aripiprazole), is now available in Canada. For those living with this lifelong disease who may be struggling with a treatment that doesn't work for them or with side effects that are difficult to tolerate, ABILIFY offers efficacy and good safety and tolerability with limited impact on weight, blood sugar and lipids - significant clinical benefits that may help patients stay on treatment longer. [More]

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , , , , , , , , ,

Permalink | Comments (2)

New market research on Bristol-Myers Squibb released

21. September 2009 07:24
This analysis examines the historical and forecast performance for BMS in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information. [More]

Posted in: Business / Finance

Tags: , , , , , , , , , , , ,

Permalink | Comments (0)

St. Petersburg Times examines decline in antipsychotic drug prescriptions for Florida children

31. March 2009 19:25
St. Petersburg Times recently examined how since the Florida Medicaid program last year began requiring physicians to receive approval before prescribing antipsychotic drugs to children younger than age six, the number of prescriptions for children in that age group has dropped by nearly 75%, according to new data from the Florida Agency for Health Care Administration. [More]

Posted in: Child Health News

Tags: , , , , , ,

Permalink | Comments (0)

Warning about use of psychiatric drugs with the elderly

17. June 2008 00:59
Health officials in the U.S. are warning doctors that prescribing certain psychiatric drugs to elderly people suffering from dementia can increase their risk of death. [More]

Posted in: Pharmaceutical News

Tags: , , , , , , , , , , , , ,

Permalink | Comments (0)

Antipsychotic drugs get FDA label changes

16. June 2008 16:32
The U.S. Food and Drug Administration today exercised its new authority under the Food and Drug Administration Amendments Act of 2007 (FDAAA) to require manufacturers of "conventional" antipsychotic drugs to make safety-related changes to prescribing information, or labeling, to warn about an increased risk of death associated with the off-label use of these drugs to treat behavioral problems in older people with dementia. [More]

Posted in: Pharmaceutical News

Tags: , , , , , , , , , , , ,

Permalink | Comments (0)

Abilify (aripiprazole) approved for acute treatment of bipolar I disorder in adolescents

1. March 2008 13:29
Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company has announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application for ABILIFY (aripiprazole) for the acute treatment of manic and mixed episodes associated with Bipolar I Disorder, with or without psychotic features in pediatric patients (10 to 17 years old). [More]

Posted in: Pharmaceutical News

Tags: , , , , , , ,

Permalink | Comments (0)

Drug to treat children with bipolar disorder gets priority review

15. November 2007 21:19
An anti-psychotic drug already approved in the U.S. to treat adults and adolescents with schizophrenia may soon be available for youngsters age 10 to 17 years of age suffering from bipolar disorder. [More]

Posted in: Pharmaceutical News

Tags: , , , , ,

Permalink | Comments (0)

Urgent need for better understanding of bipolar disease in children and adolescents

4. September 2007 00:40
The number of visits to a doctor's office that resulted in a diagnosis of bipolar disorder in children and adolescents has increased by 40 times over the last decade, reported researchers funded in part by the National Institutes of Health (NIH). [More]

Posted in: Medical Condition News

Tags: , , , , , , , , , , , , , ,

Permalink | Comments (0)

Bristol-Myers Squibb and Otsuka Pharmaceutical announce availability of 2 mg Abilify (aripiprazole) tablet

7. February 2006 14:21
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced two newly available options of Abilify (aripiprazole) -- a 2 mg tablet strength and a nonrefrigerated oral solution (1 mg/mL). [More]

Posted in: Pharmaceutical News

Tags: , , ,

Permalink | Comments (0)

FDA issues public health advisory for antipsychotic drugs

12. April 2005 09:11
The Food and Drug Administration (FDA) has issued a public health advisory to alert health care providers, patients, and patient caregivers to new safety information concerning an unapproved (i.e., “off-label”) use of certain drugs called “atypical antipsychotic drugs.” [More]

Posted in: Pharmaceutical News

Tags: , , , , , , , , , ,

Permalink | Comments (0)

FDA wants warnings put on antipsychotic drugs

11. April 2005 21:36
The Food and Drug Administration (FDA) has issued a public health advisory to health care providers, patients, and caregivers to alert them to new safety information about the use of certain unapproved or off label drugs which come under the category of “atypical antipsychotic drugs.” [More]

Posted in: Pharmaceutical News

Tags: , , , , , , , , , ,

Permalink | Comments (0)

Approval of Abilify (aripiprazole) for the treatment of acute bipolar mania

4. October 2004 07:37
Bristol-Myers Squibb and Otsuka Pharmaceutical have announced that the U.S. Food and Drug Administration (FDA) has approved Abilify (aripiprazole) for the treatment of acute bipolar mania, including manic and mixed episodes associated with bipolar disorder. [More]

Posted in: Pharmaceutical News

Tags: , , , , , , , , ,

Permalink | Comments (0)
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.